Erratum to: Advancing drug delivery systems for the treatment of multiple sclerosis
- PDF / 316,055 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 56 Downloads / 145 Views
ERRATUM
Erratum to: Advancing drug delivery systems for the treatment of multiple sclerosis Inna Tabansky1 • Mark D. Messina2,3 • Catherine Bangeranye3 • Jeffrey Goldstein2,3 Karen M. Blitz-Shabbir2 • Suly Machado2,3 • Venkatesh Jeganathan4 • Paul Wright2 • Souhel Najjar2 • Yonghao Cao4 • Warren Sands5,6 • Derin B. Keskin7 • Joel N. H. Stern1,2,3,4
•
Ó Springer Science+Business Media New York 2016
Erratum to: Immunol Res (2015) 63:58–69 DOI 10.1007/s12026-015-8719-0 Unfortunately, the author names were incorrect in the Reference 86 in the original publication of the article. The corrected reference [86] is given below.
Reference 86. Price JD, Hotta-Iwamura C, Zhao Y, Beauchamp NM, Tarbell KV. DCIR2 ? cDC2 DCs and Zbtb32 restore CD4 ? T cell tolerance and inhibit diabetes. Diabetes. 2015;64:3521–31.
The online version of the original article can be found under doi:10. 1007/s12026-015-8719-0. & Joel N. H. Stern [email protected]; [email protected] 1
Department of Neurobiology and Behavior, The Rockefeller University, New York, NY, USA
2
Department of Neurology, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
3
Department of Science Education, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA
4
Department of Autoimmunity, The Feinstein Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY, USA
5
School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA
6
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
7
Department of Cancer Immunology and AIDS, Dana FarberHarvard Cancer Institute, Boston, MA, USA
123
Data Loading...
